George Frangeskides, Chairman at ALBA, explains why the Pilbara Lithium option ‘was too good to miss’. Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Thats clever, de-merge it, then buy it back bit by bit!!!!
At least Tils will have a holding in Accustem which shatreholders of Tils will benefit. About time being ahead of timeframes given would be a welcome change. Lol.
" Prior to full commercial scaling, we expect to focus our first revenues from a small number of early adopting sites, where we may also subsidize the full cost of the test to encourage use and create further validation data. This is expected to be within 24 months of Admission"
Last year they claimed Accustem would commercialise the tests this year in Italy first, I wonder if that's another timescale that was wildly optimistic, now they seem to be saying "within 24 months of Admission"
Thanks Cloudy, I was aware of the £1m someone mentioned but hadn't spotted the £2m.
It will be interesting to see how this plays out, in terms of the SP at listing. But aside from that, I wish they'd just get on with it!! :-)
Lets hope it lists at £1 and tils buy 2m shares of the 204m shares in issue or they release eaquity.
Otherway is, it lists at 1p and they buy 200m shares through equity release and TILS will own approx 50% of Accustem.
Maybe the figure of 204m shares in issue has come from a price of 25p/share for the £2m investment (4% holding).
Another snippet from the SEC document:
RevenueStrategy
Our revenue is expected to be derived from different sources including standard private third-party and government medical insurance coverage and reimbursement models. Prior to full commercial scaling, we expect to focus our first revenues from a small number of early adopting sites, where we may also subsidize the full cost of the test to encourage use and create further validation data. This is expected to be within 24 months of Admission, subject to successful validation trials and approvals under the CLIA certification or upon the obtaining of a CE mark for the test.
BB
https://sec.report/Document/0001193125-21-078642/#rom138593_7
Below the 30.
Found it in sec form
Item 4
The objective of the Demerger was to maximise value to the shareholders of Tiziana through the further commercialization of StemPrintER™ and its assets and intellectual property. The demerger will allow the Company to continue these commercialization efforts as a separate listed company with cash reserves of approximately £1,000,000. Subject to our Ordinary Shares being admitted to a Standard Listing and to trading on the Main Market of the London Stock Exchange, Tiziana has agreed, pursuant to the terms of the Supplemental Demerger Agreement, to invest not less than £2,000,000 in our equity securities
£2mill extra not £3mill sorry.
I did read on one the documents that in the demerger agreement, that Tils are contracted to purchase shares in Accustem after listing to the value of £3mill , I remember thinking that’s the placing to enable Accustem to move forward.
One of the SEC forms I think.
May look later as busy now.
TILS was to pay $ 1.000000 on separation from Tils to accustem for general running costs from memory. At least something moving at last May sale agreement reached if not then TILS pull of one hell of a pump and dump and once again Pi's picking up the bill.
https://finance.yahoo.com/news/tiziana-life-sciences-plc-accustem-113500788.html
includes - 'Once the SEC has approved the Form 20-F (or it becomes effective), the final aspect of the distribution will be complete and Accustem will be an entirely separate entity and will move forward with plans to secure its own listing.
In the meantime, Tiziana shareholders are directed to the Accustem website at http://www.accustem.com/, where all further developments and news will be published.'
But have no idea what the implications are to the SP, especially as Accustem is not currently quoted. Seems very strange.
Can you post the supporting links please? I've not been aware of either Tils committing to further fund Accustem or it being sold, other than the usual speculative stuff here.
Tils is committed to inject cash into Accustem on floatation maybe, but as it’s ’our money’ we will own more of Accustem, and just seen the Articles of Association for ACM (Accustem) I think it’s gonna be sold.Anyone else seen this as my memory is questionable, Need foralumab for Alzheimer’s. Happy days